Expert Coronavirus Updates | Session 15

Posted by Mike Biselli on 8.5.2020

Important Podcast Links:

Welcome to episode sixty-six of Passionate Pioneers.

With the COVID-19 outbreak bringing the world to its knees, it’s encouraging to see executives and organizations quickly respond to the emergency that’s right in front of us.

This only speaks to who we are as a nation and the types of entrepreneurs that make this country so great.

In this episode, I’m joined by Josh Disbrow, Chief Executive Officer of Aytu Bioscience. He’ll help us gain a better understanding about antibodies and COVID-19. Josh shares his organization’s journey in receiving their emergency authorization use for their COVID-19 rapid antibody test and why Aytu BioScience is perfectly positioned to help fight the global pandemic. 

We also receive a sneak peek into the company’s future innovation roadmap and why these new and forthcoming technologies have significant potential to save many lives impacted by this devastating disease. 

If you want to stay updated about Aytu Bioscience and its COVID-19 efforts, as well as the innovative products they are creating to help battle the pandemic, then you should definitely listen to this episode!

Episode Highlights:

  • How Aytu Bioscience is helping fight COVID-19
  • Why antibody testing is important during the pandemic
  • How antibodies help with creating a vaccine
  • Other technologies Aytu Bioscience is known for before the outbreak
  • The process of how antibody testing got into the marketplace
  • What emergency use authorization is and why it is important
  • How Aytu Bioscience created their COVID-19 antibody test
  • Future technology that Aytu Bioscience is creating

About Our Guest:

Josh Disbrow is the Co-Founder, Chairman, and Chief Executive Officer of Aytu BioScience, Inc. (NASDAQ: AYTU). Founded in 2015, Aytu BioScience is a specialty pharmaceutical company engaged in the global commercialization of novel prescription therapeutics and consumer healthcare products. Josh has been in the life sciences industry for over twenty three years across pharmaceuticals, diagnostics, and medical devices. Prior to co-founding Aytu, Josh served as the Chief Operating Officer of Colorado-based Ampio Pharmaceuticals (NYSE MKT: AMPE) and co-founded the Luoxis Diagnostics subsidiary. 

Prior to joining Ampio in 2012, he served as Vice President of Commercial Operations at Arbor Pharmaceuticals, a privately-held specialty pharmaceutical company. Josh began as Arbor Pharmaceuticals’ second employee and oversaw the launch and subsequent growth of the company’s commercial operations. Josh led the commercial organization prior to the launch of the company’s first product, subsequently launching numerous products and scaling the team across sales, marketing, managed care, sales training, distribution, and national accounts. In less than four years, Arbor grew from a company without any product revenues to a company with net sales of over $125 million. Josh and his twin brother Jarrett exited Arbor when private equity firm KKR acquired their stake in the company, valuing the company at over $1 billion.

Prior to joining Arbor, Josh was the Director of Marketing at LipoScience (NASDAQ: LPDX), a specialty cardiovascular in vitro diagnostic company that was sold to LabCorp (NYSE: LH). Previously, Josh was in sales leadership at Cyberonics (Now LivaNova plc, NASDAQ: LIVN), a medical device company commercializing implantable neuromodulation devices. Josh started his career as a sales representative at Glaxo Wellcome (now GlaxoSmithKline plc). Josh is on the board of directors of Zynex, Inx, (NASDAQ: ZYXI) and is Chairman of the Nominating and Governance. Zynex is a medical device company focused on electrotherapy and pain management. He holds a Bachelor of Science in Management from North Carolina State University and a Master of Business Administration from Wake Forest University. Josh and his wife Lesley have been married for 21 years and live in Denver with their two children.

Links Supporting this Episode: